• Something wrong with this record ?

Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study

J. Donadieu, IA. Larabi, M. Tardieu, J. Visser, C. Hutter, E. Sieni, N. Kabbara, M. Barkaoui, J. Miron, F. Chalard, P. Milne, J. Haroche, F. Cohen, Z. Hélias-Rodzewicz, N. Simon, M. Jehanne, A. Kolenova, A. Pagnier, N. Aladjidi, P. Schneider, G....

. 2019 ; 37 (31) : 2857-2865. [pub] 20190912

Language English Country United States

Document type Journal Article, Multicenter Study, Observational Study, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20023533

PURPOSE: Off-label use of vemurafenib (VMF) to treat BRAFV600E mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. PATIENTS AND METHODS: Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were classified according to risk organ involvement: liver, spleen, and/or blood cytopenia. The main evaluation criteria were adverse events (Common Terminology Criteria for Adverse Events [version 4.3]) and therapeutic responses according to Disease Activity Score. RESULTS: LCH extent was distributed as follows: 44 with positive and 10 with negative risk organ involvement. Median age at diagnosis was 0.9 years (range, 0.1 to 6.5 years). Median age at VMF initiation was 1.8 years (range, 0.18 to 14 years), with a median follow-up of 22 months (range, 4.3 to 57 months), whereas median treatment duration was 13.9 months (for 855 patient-months). At 8 weeks, 38 complete responses and 16 partial responses had been achieved, with the median Disease Activity Score decreasing from 7 at diagnosis to 0 (P < .001). Skin rash, the most frequent adverse event, affected 74% of patients. No secondary skin cancer was observed. Therapeutic plasma VMF concentrations (range, 10 to 20 mg/L) seemed to be safe and effective. VMF discontinuation for 30 patients led to 24 LCH reactivations. The blood BRAFV600E allele load, assessed as circulating cell-free DNA, decreased after starting VMF but remained positive (median, 3.6% at diagnosis, and 1.6% during VMF treatment; P < .001) and was associated with a higher risk of reactivation at VMF discontinuation. None of the various empirical therapies (hematopoietic stem-cell transplantation, cladribine and cytarabine, anti-MEK agent, vinblastine, etc) used for maintenance could eradicate the BRAFV600E clone. CONCLUSION: VMF seemed safe and effective in children with refractory BRAFV600E-positive LCH. Additional studies are needed to find effective maintenance therapy approaches.

Azienda Ospedaliero Universitaria A Meyer Florence Italy

Cambridge University Hospitals Cambridge United Kingdom

Centre Hospitalier du Nord Zgharta Lebanon Rafic Hariri University Hospital Beirut Lebanon

Centre Hospitalier Universitaire d'Amiens Amiens France

Centre Hospitalier Universitaire de Bordeaux Bordeaux France

Centre Hospitalier Universitaire de Grenoble Grenoble France

Centre Hospitalier Universitaire de Lille Lille France

Centre Hospitalier Universitaire de Poitiers Poitiers France

Centre Hospitalier Universitaire de Rouen Rouen France

Centre Hospitalier Universitaire de Toulouse Toulouse France

Centre Hospitalier Universitaire Félix Guyon La Réunion France

Centre Hospitalier Universitaire La Pitié Salpêtrière Charles Foix Paris France

Centre Hospitalier Universitaire Pitié Salpêtrière Paris France

Centre Hospitalier Universitaire R Poincaré Garches France

Charité University Medicine Berlin Berlin Germany

Comenius University Children's Hospital Limbova 1 Bratislava Slovakia

Dmitriy Rogachev National Center for Pediatric Hematology Oncology and Immunology Moscow Russia

Great Ormond Street Hospital London United Kingdom

Hôpital Mustapha Mustapha Algeria

Hôpital Sainte Marguerite Marseille France

Hôpital Universitaire des Enfants Reine Fabiola Brussels Belgium

Hôpitaux Universitaires de Genève Geneva Switzerland

Medical University of Vienna Vienna Austria

Newcastle University Newcastle upon Tyne United Kingdom

Schneider Children's Medical Center Petah Tikva Israel

The Edmond and Lily Safra Children's Hospital Tel Hahsomer Israel

Trousseau Hospital Paris France

Trousseau Hospital Paris France Université Paris Saclay Boulogne Billancourt France

Universitätsklinikum Frankfurt Frankfurt am Main Germany

Universitätsklinikum Münster Klinik für Kinder und Jugendmedizin Pädiatrische Hämatologie und Onkologie Münster Germany

Université Paris Saclay Boulogne Billancourt France

Université Paris Sorbonne Cité Paris France

University Hospital Minsk Belarus

University Hospital Motol Prague Czech Republic

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20023533
003      
CZ-PrNML
005      
20201214130318.0
007      
ta
008      
201125s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.19.00456 $2 doi
035    __
$a (PubMed)31513482
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Donadieu, Jean $u Trousseau Hospital, Paris, France.
245    10
$a Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study / $c J. Donadieu, IA. Larabi, M. Tardieu, J. Visser, C. Hutter, E. Sieni, N. Kabbara, M. Barkaoui, J. Miron, F. Chalard, P. Milne, J. Haroche, F. Cohen, Z. Hélias-Rodzewicz, N. Simon, M. Jehanne, A. Kolenova, A. Pagnier, N. Aladjidi, P. Schneider, G. Plat, A. Lutun, A. Sonntagbauer, T. Lehrnbecher, A. Ferster, V. Efremova, M. Ahlmann, L. Blanc, J. Nicholson, A. Lambilliote, H. Boudiaf, A. Lissat, K. Svojgr, F. Bernard, S. Elitzur, M. Golan, D. Evseev, M. Maschan, A. Idbaih, O. Slater, M. Minkov, V. Taly, M. Collin, JC. Alvarez, JF. Emile, S. Héritier,
520    9_
$a PURPOSE: Off-label use of vemurafenib (VMF) to treat BRAFV600E mutation-positive, refractory, childhood Langerhans cell histiocytosis (LCH) was evaluated. PATIENTS AND METHODS: Fifty-four patients from 12 countries took VMF 20 mg/kg/d. They were classified according to risk organ involvement: liver, spleen, and/or blood cytopenia. The main evaluation criteria were adverse events (Common Terminology Criteria for Adverse Events [version 4.3]) and therapeutic responses according to Disease Activity Score. RESULTS: LCH extent was distributed as follows: 44 with positive and 10 with negative risk organ involvement. Median age at diagnosis was 0.9 years (range, 0.1 to 6.5 years). Median age at VMF initiation was 1.8 years (range, 0.18 to 14 years), with a median follow-up of 22 months (range, 4.3 to 57 months), whereas median treatment duration was 13.9 months (for 855 patient-months). At 8 weeks, 38 complete responses and 16 partial responses had been achieved, with the median Disease Activity Score decreasing from 7 at diagnosis to 0 (P < .001). Skin rash, the most frequent adverse event, affected 74% of patients. No secondary skin cancer was observed. Therapeutic plasma VMF concentrations (range, 10 to 20 mg/L) seemed to be safe and effective. VMF discontinuation for 30 patients led to 24 LCH reactivations. The blood BRAFV600E allele load, assessed as circulating cell-free DNA, decreased after starting VMF but remained positive (median, 3.6% at diagnosis, and 1.6% during VMF treatment; P < .001) and was associated with a higher risk of reactivation at VMF discontinuation. None of the various empirical therapies (hematopoietic stem-cell transplantation, cladribine and cytarabine, anti-MEK agent, vinblastine, etc) used for maintenance could eradicate the BRAFV600E clone. CONCLUSION: VMF seemed safe and effective in children with refractory BRAFV600E-positive LCH. Additional studies are needed to find effective maintenance therapy approaches.
650    _2
$a mladiství $7 D000293
650    _2
$a věkové faktory $7 D000367
650    _2
$a dítě $7 D002648
650    _2
$a předškolní dítě $7 D002675
650    _2
$a léková rezistence $7 D004351
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a histiocytóza z Langerhansových buněk $x diagnóza $x farmakoterapie $x genetika $7 D006646
650    _2
$a lidé $7 D006801
650    _2
$a kojenec $7 D007223
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mutace $7 D009154
650    _2
$a inhibitory proteinkinas $x škodlivé účinky $x terapeutické užití $7 D047428
650    _2
$a protoonkogenní proteiny B-raf $x antagonisté a inhibitory $x genetika $7 D048493
650    _2
$a stupeň závažnosti nemoci $7 D012720
650    _2
$a signální transdukce $7 D015398
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
650    _2
$a vemurafenib $x škodlivé účinky $x terapeutické užití $7 D000077484
651    _2
$a Evropa $7 D005060
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a pozorovací studie $7 D064888
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Larabi, Islam Amine $u Centre Hospitalier Universitaire R.-Poincaré, Garches, France.
700    1_
$a Tardieu, Mathilde $u Centre Hospitalier Universitaire de Grenoble, Grenoble, France.
700    1_
$a Visser, Johannes $u Cambridge University Hospitals, Cambridge, United Kingdom.
700    1_
$a Hutter, Caroline $u Medical University of Vienna, Vienna, Austria.
700    1_
$a Sieni, Elena $u Azienda Ospedaliero-Universitaria A. Meyer, Florence, Italy.
700    1_
$a Kabbara, Nabil $u Centre Hospitalier du Nord, Zgharta, Lebanon. Rafic Hariri University Hospital, Beirut, Lebanon.
700    1_
$a Barkaoui, Mohamed $u Trousseau Hospital, Paris, France.
700    1_
$a Miron, Jean $u Trousseau Hospital, Paris, France.
700    1_
$a Chalard, François $u Trousseau Hospital, Paris, France.
700    1_
$a Milne, Paul $u Newcastle University, Newcastle upon Tyne, United Kingdom.
700    1_
$a Haroche, Julien $u Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France.
700    1_
$a Cohen, Fleur $u Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France.
700    1_
$a Hélias-Rodzewicz, Zofia $u Université Paris-Saclay, Boulogne-Billancourt, France.
700    1_
$a Simon, Nicolas $u Hôpital Sainte Marguerite, Marseille, France.
700    1_
$a Jehanne, Mathilde $u Centre Hospitalier Universitaire Félix-Guyon (Saint-Denis), La Réunion, France.
700    1_
$a Kolenova, Alexandra $u Comenius University Children's Hospital Limbova 1, Bratislava, Slovakia.
700    1_
$a Pagnier, Anne $u Centre Hospitalier Universitaire de Grenoble, Grenoble, France.
700    1_
$a Aladjidi, Nathalie $u Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.
700    1_
$a Schneider, Pascale $u Centre Hospitalier Universitaire de Rouen, Rouen, France.
700    1_
$a Plat, Geneviève $u Centre Hospitalier Universitaire de Toulouse, Toulouse, France.
700    1_
$a Lutun, Anne $u Centre Hospitalier Universitaire d'Amiens, Amiens, France.
700    1_
$a Sonntagbauer, Anne $u Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
700    1_
$a Lehrnbecher, Thomas $u Universitätsklinikum Frankfurt, Frankfurt am Main, Germany.
700    1_
$a Ferster, Alina $u Hôpital Universitaire des Enfants Reine Fabiola, Brussels, Belgium.
700    1_
$a Efremova, Viktoria $u University Hospital, Minsk, Belarus.
700    1_
$a Ahlmann, Martina $u Universitätsklinikum Münster Klinik für Kinder- und Jugendmedizin-Pädiatrische Hämatologie und Onkologie, Münster, Germany.
700    1_
$a Blanc, Laurence $u Centre Hospitalier Universitaire de Poitiers, Poitiers, France.
700    1_
$a Nicholson, James $u Cambridge University Hospitals, Cambridge, United Kingdom.
700    1_
$a Lambilliote, Anne $u Centre Hospitalier Universitaire de Lille, Lille, France.
700    1_
$a Boudiaf, Houda $u Hôpital Mustapha, Mustapha, Algeria.
700    1_
$a Lissat, Andrej $u Charité-University Medicine Berlin, Berlin, Germany.
700    1_
$a Svojgr, Karel $u University Hospital Motol, Prague, Czech Republic.
700    1_
$a Bernard, Fanette $u Hôpitaux Universitaires de Genève, Geneva, Switzerland.
700    1_
$a Elitzur, Sarah $u Schneider Children's Medical Center, Petah Tikva, Israel.
700    1_
$a Golan, Michal $u The Edmond and Lily Safra Children's Hospital, Tel-Hahsomer, Israel.
700    1_
$a Evseev, Dmitriy $u Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
700    1_
$a Maschan, Michael $u Dmitriy Rogachev National Center for Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
700    1_
$a Idbaih, Ahmed $u Centre Hospitalier Universitaire La Pitié-Salpêtrière-Charles Foix, Paris, France.
700    1_
$a Slater, Olga $u Great Ormond Street Hospital, London, United Kingdom.
700    1_
$a Minkov, Milen $u Medical University of Vienna, Vienna, Austria.
700    1_
$a Taly, Valerie $u Université Paris Sorbonne Cité, Paris, France.
700    1_
$a Collin, Matthew $u Newcastle University, Newcastle upon Tyne, United Kingdom.
700    1_
$a Alvarez, Jean-Claude $u Centre Hospitalier Universitaire R.-Poincaré, Garches, France.
700    1_
$a Emile, Jean-François $u Université Paris-Saclay, Boulogne-Billancourt, France.
700    1_
$a Héritier, Sébastien $u Trousseau Hospital, Paris, France. Université Paris-Saclay, Boulogne-Billancourt, France.
773    0_
$w MED00002596 $t Journal of clinical oncology : official journal of the American Society of Clinical Oncology $x 1527-7755 $g Roč. 37, č. 31 (2019), s. 2857-2865
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31513482 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20201214130315 $b ABA008
999    __
$a ok $b bmc $g 1595852 $s 1114209
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 37 $c 31 $d 2857-2865 $e 20190912 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options